author-photo

Ken-ichi Tabata

Kitasato University

111

Papers

985

Citations

Citation Trend

Filter By

Papers (75) Sort By

Journal Conference Others

MO27-3 Clinical outcomes of metastasis-directed radiation therapy (MDRT) for oligometastatic prostate cancer

2021 Annals of Oncology
- Ken-ichi Tabata
Show All
- Source
- Cite
- Save
Citations (0)
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.

2020 Cancer Science
Show All
- Source
- Cite
- Save
Citations (4)
Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Complete biochemical response following metastasis-directed radiotherapy for oligometastatic prostate cancer: A case report

2020 Urology case reports
Show All
- Source
- Cite
- Save
Citations (0)
The development and validation of a prognostic nomogram and nomogram application software among men treated with abiraterone acetate and/or enzalutamide for metastatic castration-resistant prostate cancer

2020
Show All
- Source
- Cite
- Save
Citations (0)
Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients.

2020 Japanese Journal of Radiology
Show All
- Source
- Cite
- Save
Citations (1)
231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer

2020 Asian Journal of Urology
Show All
- Source
- Cite
- Save
Citations (1)
A new predictive model for prognosis in oligometastatic prostate cancer

2020
Show All
- Source
- Cite
- Save
Citations (0)
Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)